ACE2 News and Research

RSS

Could JAK blockers help treat COVID-19?

A new study published in the journal Science Immunology in May 2020 reports that compounds that safely inhibit the JAK protein could be useful in treating COVID-19.

12 May 2020

SARS-CoV-2 cell entry affinity varies across different host species

A new study from India, currently available on the preprint server bioRxiv*, estimated the probability and readiness of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) to infect cells of different animal species – and revealed many of them that could act as disease carriers.

12 May 2020

Potential for COVID-19 transmission from human eye

A new study published on the preprint server bioRxiv* in May 2020 reports the presence of ACE2 receptors in the eye at high concentrations. These molecules are the entry points for the SARS-CoV-2 virus that is causing the ongoing COVID-19 pandemic.

12 May 2020

Does cholesterol play a role in COVID-19?

A new study published on the preprint server bioRxiv in May 2020 suggests that the strikingly increased mortality in COVID-19 patients who are either old or also have high blood pressure, diabetes, cardiovascular disease is due to high tissue cholesterol levels. It also indicates the role of a healthy diet, by showing that polyunsaturated fatty acids (PUFA) in blood oppose the effects of cholesterol and thus the risk for severe COVID-19 symptoms.

12 May 2020

Symptomatic COVID-19 patients less likely to be smokers

As the COVID-19 pandemic rages in many parts of the world, a new study shows that smoking may not play a significant role in increasing the severity of illness in these patients. The study is published on the preprint server medRxiv* in May 2020.

12 May 2020

SARS-CoV-2 binds heparan sulfate, preventing host cell infection

A new study published in May 2020 on the preprint server bioRxiv shows that the SARS-CoV-2 virus can bind to a sugar molecule called heparan sulfate (HS), thereby hindering its entry into the host cell.

12 May 2020

Study sheds more light on the evolutionary ancestry of SARS-CoV-2

There is ongoing debate among policymakers and the general public about where SARS-CoV-2, the virus that causes COVID-19, came from. While researchers consider bats the most likely natural hosts for SARS-CoV-2, the origins of the virus are still unclear.

12 May 2020

SARS-CoV-2 could spread through surface of the eyes

Researchers from Johns Hopkins University School of Medicine have found that the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus could spread via ocular or eye surfaces. This is because the receptor where the virus binds – the ACE2, is also expressed on human eyes, they note.

11 May 2020

Genomic sequences from all over the world help fight SARS-CoV-2

As the COVID-19 pandemic rages across the world, killing hundreds of thousands and infecting over 4.1 million, researchers are racing against time to understand the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The SARS-CoV-2 genome has now been sequenced in many different regions of the world, and researchers are collaborating by sharing information to better understand the make-up and mutations that the virus has undergone.

11 May 2020

Scientists explore why some COVID-19 patients lose their sense of smell

Doctors have reported that partial or total loss of the sense of smell is often an early symptom of infection with SARS-CoV-2, the virus that causes COVID-19.

11 May 2020

Study finds bowel abnormalities in patients with COVID-19

Patients with COVID-19 can have bowel abnormalities, including ischemia, according to a new study published today in the journal Radiology.

11 May 2020

Italy develops vaccine candidate that neutralizes SARS-CoV-2 in mice

As the world grapples with the coronavirus disease (COVID-19), scientists race to develop treatments and vaccines to combat the viral infection. Though many ongoing trials show promise in fighting the novel coronavirus, Italian researchers claim they have developed a vaccine that can neutralize severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in animal cells.

10 May 2020

No evidence COVID-19 is spread by fecal-oral transmission

A new study published on the preprint server medRxiv* in May 2020 shows that in patients who test positive for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in pharyngeal and fecal samples, the virus persists longer in the fecal samples than in the pharyngeal samples. However, fecal-oral transmission does not appear to occur.

10 May 2020

Human neutralizing antibody pair blocks COVID-19-ACE2 binding

With the ongoing COVID-19 pandemic carving its deadly path across the world, and no end in sight in the immediate future, researchers are working furiously to bring out an effective therapeutic drug or vaccine that will stop the virus in its tracks.

10 May 2020

Neutralizing SARS-CoV-2 via S protein

A new study published on the preprint server bioRxiv* in May 2020 reports on a method to block severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) by destroying its main spike protein, which is responsible for attachment to the host cell membrane.

10 May 2020

Study shows COVID-19 vulnerability is highly dependent on host genetic architecture

A new US study available on the preprint server medRxiv reveals certain genetic variations that are associated with infection susceptibility and diverse clinical presentation of coronavirus disease (COVID-19) – including asymptomatic cases and severe forms of the disease in younger patients.

10 May 2020

ACE inhibitors should not be discontinued over fears about COVID-19, say researchers

Researchers in Europe have found no evidence to support previous reports that the use of drugs that target the renin-angiotensin-aldosterone system (RAAS) increases susceptibility to coronavirus disease 2019 (COVID-19). The research is published in the European Heart Journal.

10 May 2020

Repurposing existing drugs is a more rapid alternative than developing COVID-19 vaccine

Repurposing existing medicines focused on known drug targets is likely to offer a more rapid hope of tackling COVID-19 than developing and manufacturing a vaccine, argue an international team of scientists in the British Journal of Pharmacology today.

8 May 2020

Predicting the dose for repurposing nitazoxanide in COVID-19

A new study published on the preprint server medRxiv in May 2020 reports a model that could help evolve appropriate dosage protocols for future clinical trials of the repurposed drug nitazoxanide in COVID-19 prevention and treatment. The researchers say, “It was possible to achieve plasma and lung tizoxanide concentrations, using proven safe doses of nitazoxanide, that exceed the EC90 for SARS-CoV-2.”

7 May 2020

Twist Bioscience Identifies Competitive Antibodies for SARS-CoV-2

Twist Bioscience Corporation has identified competitive antibodies to SARS-CoV-2, which could potentially be used for diagnostic tests and treatments.

7 May 2020